早日实现全球消除丙肝的美好愿景~ 参考文献: [1] http://www./news.do?method=largeInfo&id=314651 [2] https://www.sohu.com/a/361751820_262785 [3] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 中华传染病杂志, 2020, 38(01):9-28. [4] Mangia A, Milligan S, Khalili M, et al. GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts[J]. Journal of Hepatology, 2019, 70(1): e2-e3. [5] Mathur P, Kottilil S, Wilson E. Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients[J]. Antiviral therapy, 2019, 24: 1-10. [6] 索磷维伏片(沃士韦®)中国说明书,核准日期:2019年12月18日 [7] Bourlière M, Gordon S C, Flamm S L, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection[J]. New England Journal of Medicine, 2017, 376(22): 2134-2146. [8] Roberts,EASL 2017,SAT-280. [9] https://www./regulatory-information/selected-amendments-fdc-act/21st-century-cures-act [10] Sherman R E, Anderson S A, Dal Pan G J, et al. Real-World Evidence-What Is It and What Can It Tell Us?[J]. The New England Journal of Medicine, 2016, 375(23): 2293. [11] Bacon B, et al. ILC2019. THU-116 [12] Vermehren J, et al.ILC2019.THU-188 [13] Hezode C,et al.ILC 2019.THU-142 [14] Belperio P S, Shahoumian T A, Loomis T P, et al. Real‐world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct‐acting antiviral experienced hepatitis C patients[J]. Journal of viral hepatitis, 2019, 26(8): 980-990. [15] European Association for The Study of The Liver. EASL recommendations on treatment of hepatitis C 2018[J]. Journal of hepatology, 2018, 69(2): 461-511. [16] World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[J]. 2018. [17] American Association for the Study of Liver Diseases, Infectious Disease Society of North America. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.. Accessed Nov, 2019 [18] 国家基本医疗保险、工伤保险和生育保险药品目录. (医保发〔2019〕65号) [19] Wei L, Xie Q, Huang Y, et al. Safety and Efficacy of sofosbuvir/velpatasvir in genotype 1-6 HCV-infected patients in China: Results from a phase 3 clinical trial[C]//Hepatology. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2018, 68: 379A-379A. [20] Agarwal, EASL 2016, Poster SAT-195 |
|